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Background: The purpose of this study was to compare differences in visual outcomes, 
higher-order aberrations, contrast sensitivity, and dry eye in patients undergoing photorefractive 
keratectomy using wavefront-guided VISX CustomVue™ and wavefront-optimized WaveLight® 
Allegretto platforms.
Methods: In this randomized, prospective, single-masked, fellow-eye study, photorefractive 
keratectomy was performed on 46 eyes from 23 patients, with one eye randomized to   WaveLight 
Allegretto, and the fellow eye receiving VISX CustomVue. Three-month postoperative outcome 
measures included uncorrected distance visual acuity, corrected distance visual acuity, refractive 
error, root mean square of total and grouped higher-order aberrations, contrast sensitivity, and 
Schirmer’s testing.
Results: Mean values for uncorrected distance visual acuity (logMAR) were −0.03 ± 0.07 
and −0.06 ± 0.09 in the wavefront-optimized and wavefront-guided groups, respectively 
(P = 0.121). Uncorrected distance visual acuity of 20/20 or better was achieved in 91% of eyes 
receiving wavefront-guided photorefractive keratectomy, and 87% of eyes receiving wavefront-
optimized photorefractive keratectomy, whereas uncorrected distance visual acuity of 20/15 
was achieved in 35% of the wavefront-optimized group and 64% of the wavefront-guided group 
(P $ 0.296). While root mean square of total higher-order aberration, coma, and trefoil tended to 
increase in the wavefront-optimized group (P = 0.091, P = 0.115, P = 0.459, respectively), only 
spherical aberration increased significantly (P = 0.014). Similar increases were found in wave-
front-guided root mean square of total higher-order aberration (P = 0.113), coma (P = 0.403), 
trefoil (P = 0.603), and spherical aberration (P = 0.014). There was no significant difference in 
spherical aberration change when comparing the two platforms. The wavefront-guided group 
showed an increase in contrast sensitivity at 12 cycles per degree (P = 0.013).
Conclusion: Both VISX CustomVue and WaveLight Allegretto platforms performed equally in 
terms of visual acuity, safety, and predictability in photorefractive keratectomy. The wavefront-
guided group showed slightly improved contrast sensitivity. Both lasers induced a comparable 
degree of statistically significant spherical aberration, and tended to increase other higher-order 
aberration measures as well.
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Introduction
Reoperation rates for primary conventional myopic photorefractive keratectomy 
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keratectomy is capable of correcting lower-order aberrations, 
such as hyperopia, myopia, and astigmatism. However, the 
higher-order aberrations, such as coma, spherical aberra-
tion, and trefoil, are induced by (and remain uncorrected in) 
traditional photorefractive keratectomy.4–6
For patients undergoing traditional photorefractive 
keratectomy, image quality may suffer as a result of induced 
higher-order aberrations.4,7–11 Advanced optical measure-
ments and more sophisticated laser algorithms are found 
in wavefront-based treatments, which have been shown to 
diminish induced higher-order aberrations and increase 
predictability of visual outcomes compared with traditional 
keratorefractive surgery.12–16 With the development of mul-
tiple wavefront-based platforms, it is important to ascertain 
if there are significant differences in visual outcomes and 
higher-order aberrations between specific wavefront-guided 
and wavefront-optimized lasers used in photorefractive 
keratectomy. Wavefront-guided laser ablations utilize pre-
operative wavefront aberrometer data to treat higher-order 
and lower-order aberrations. These data are strictly relied 
upon for the final treatment pattern. In contrast, wavefront-
optimized laser ablations utilize preoperative refraction data 
for the treatment pattern. Wavefront-optimized platforms 
deliver more laser pulses to the periphery, which maintains 
the prolate structure of the cornea, and thereby minimizes 
higher-order aberrations.
Based on our most recent literature search using the 
PubMed keywords “wavefront”, “wavefront-guided”, 
“wavefront-optimized”, “photorefractive keratectomy”, 
“photorefractive keratectomy”, and “higher-order aber-
ration”, there are no known published studies comparing 
wavefront-guided lasers with wavefront-optimized lasers in 
patients undergoing photorefractive keratectomy. However, 
laser in situ keratomileusis (LASIK) studies have compared 
these two lasers, with some studies suggesting an advantage 
to wavefront-guided platforms,17–20 and others showing no 
significant difference between the two.21,22 In this prospective, 
randomized, fellow-eye study, we compared the wavefront-
guided VISX CustomVue platform (Abbott Medical Optics, 
Santa Ana, CA) with the wavefront-optimized WaveLight 
Allegretto platform (Alcon Inc, Hüenberg, Switzerland) in 
the same patient undergoing photorefractive keratectomy, 
with respect to visual acuity, refractive error, higher-order 
aberrations, contrast sensitivity, and dry eye.
Methods and materials
This prospective, single-masked, randomized, fellow-
eye study evaluated and compared the outcomes of 
  photorefractive keratectomy performed in 23 patients 
(46 eyes) using the VISX CustomVue laser system and the 
WaveLight Allegretto laser system. Patients were recruited 
and enrolled at the John A Moran Eye Center, Department 
of Ophthalmology and Visual Science, University of Utah, 
between November 2010 and July 2011. All patients were 
older than 21 years.
The University of Utah Hospital institutional review 
board approved the research protocol in accordance with the 
tenets of the Declaration of Helsinki. All patients provided 
informed consent after they received an explanation of the 
procedure, including all risks and benefits. All patients 
had a preoperative discussion of relevant medical history, 
including history of herpetic eye disease and family history 
of keratoconus.
Patients were excluded if they had a history of clinically 
significant lens opacity, previous corneal or intraocular sur-
gery, thin corneas, keratoconus, unstable refraction, amblyo-
pia, or autoimmune disease, and also if they were pregnant 
or breastfeeding, or on immunosuppressive therapy. Patients 
desiring monovision were not included in the study.
Eligible patients were scheduled for bilateral photorefrac-
tive keratectomy and correction for distance in both eyes. 
The patients were randomly assigned (Research Random-
izer software, Urbaniak, http:\\www.randomizer.org) to 
treatment in one eye with the WaveLight Allegretto system 
(wavefront-optimized group), which utilizes the WaveLight® 
Allegretto 400 Hz Wave® Eye-Q Laser. The fellow eye was 
assigned treatment with the VISX CustomVueTM STAR S4 
IRTM Excimer Laser with ActiveTrackTM iris registration 
(wavefront-guided group).
Soft contact lenses were discontinued 2 weeks before 
screening and rigid gas-permeable contact lenses were 
discontinued 6 weeks before screening. All patients had a 
preoperative examination including manifest refraction and 
cycloplegic refraction, uncorrected distance visual acuity, 
corrected distance visual acuity, tonometry, slit lamp exami-
nation, and dilated fundus evaluation. Corneal topography 
and thickness were measured using the Pentacam (Oculus 
Optikgeräte GmbH, Wetzlar, Germany) and Humphrey Atlas 
(Carl Zeiss Meditec Inc, Jena, Germany) systems. Pupil size 
was measured in the dark using the Colvard pupillometer 
(Oasis Medical Inc, Glendora, CA). Contrast sensitivity was 
performed using the VectorVision CSV-1000 (Dayton, OH) 
chart in controlled mesopic conditions (70 lux) at 3, 6, 12, 
and 18 cycles per degree (cpd). Schirmer’s testing evalua-
tion for dry eye was measured in millimeters with topical 
anesthetic after 5 minutes. Manifest refraction and wavefront Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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measurements were repeated on two separate visits to ensure 
refractive stability.
All eyes received five preoperative wavefront analyses 
using the VISX CustomVue WaveScan aberrometer v3.62 
(Fourier) without pharmacologic intervention, under mesopic 
conditions, with a minimum pupil diameter of 6.0 mm. The 
emmetropic correction target was based on manifest refrac-
tion, topography, and wavefront analysis for the wavefront-
guided group. For the wavefront-optimized group, the 
emmetropic correction target was based on topography and 
manifest refraction. Iris registration was obtained for eyes 
receiving wavefront-guided treatment. A physician-adjust-
ment factor was used based on previously established Moran 
Laser Center wavefront-guided photorefractive keratectomy 
nomograms for the laser system used for surgery. The 
nomograms were generated using Datagraph-med Outcomes 
Analysis Software for Refractive Surgery (version 3.20a; 
Ingenieurbüro Pieger GmbH, Wendelstein, Germany).
Prior to laser treatment, ethanol diluted to 20% in sterile 
water was placed on the cornea in an 8.5 mm Camellin-style 
laser epithelial keratomileusis (LASEK) alcohol fixation 
well (Katena Products Inc, Denville, NJ) for 35 seconds. 
Epithelial removal was performed with a Sloane LASEK 
epithelial micro hoe (Katena Products Inc). For stromal abla-
tions greater than 65 mm (n Z 17), a circular sponge soaked 
in mitomycin C 0.02% was applied for 20 seconds. The eye 
was then immediately flushed with 15 mL of a chilled balanced 
salt solution, after which a bandage contact lens (Softlens 
Plano T, Bausch and Lomb, Rochester, NY) was placed. All 
surgeries were performed by MM and MDM.
Postoperatively, one drop of gatifloxacin 0.3%   (Allergan 
Inc, Irvine, CA), prednisolone acetate 1.0% (Allergan 
Inc), and ketorolac tromethamine 0.4% (Allergan Inc) was 
instilled. Ketorolac tromethamine 0.4% was administered 
four times a day for the first 72 hours and then discontinued. 
Gatifloxacin 0.3% and prednisolone acetate were contin-
ued four times a day for 1 week with a subsequent steroid 
taper over 2–3 months. Bandage contact lenses were removed 
upon complete epithelial healing, typically 3–5 days after 
surgery.
Data were collected at 1 day, 1 week, and 1 and 3 months 
after surgery. Uncorrected and corrected distance visual 
acuity were both recorded in Snellen notation and logarithm 
of the minimum angle of resolution (logMAR) format. 
Contrast sensitivity and Schirmer’s testing were performed. 
Higher-order aberrations, including root mean square of 
total higher-order aberration, coma Z(3,1), trefoil Z(3,3), 
and spherical aberration Z(4,0) were measured using the 
WaveScan aberrometer. Undilated scans of both eyes were 
taken at 3 months postoperatively regardless of the wavefront 
platform used for treatment. The Quality of Life Impact of 
Refractive Correction (QIRC) survey instrument was used to 
record subjective outcomes, as previously described.23
statistical analysis
After the study was completed, the results were compiled 
and the data were unmasked for statistical analysis. Manifest 
refraction, refractive error, visual acuity, contrast sensitivity, 
higher-order aberration values for coma, trefoil, and sphere, 
and root mean square of higher-order aberration wavefront 
values were treated as continuous variables and analyzed for 
statistical significance using the Student’s t-test. A P value 
of 0.05 was considered statistically significant. Data analysis 
was performed using Microsoft Excel (Microsoft Corp, 
Redmond, WA).
Results
Twenty-three patients (46 eyes) with 3 months of follow-up 
were evaluated in this study. The study population consisted 
of 18 men and five women of mean age 31.4 ± 5.8 years, with 
no significant differences in preoperative corrected distance 
visual acuity and refraction (Table 1).
Visual acuity
Uncorrected and corrected distance visual acuity was not 
statistically different between the groups at 1 or 3 months 
(Table 2). At 3 months postoperatively, 20/15 uncorrected 
distance visual acuity was achieved in 35% of wavefront-
optimized eyes and 64% of wavefront-guided eyes, and 20/20 
uncorrected distance visual acuity was achieved by 87% and 
91% of the eyes in both groups, respectively (Table 3).
Safety, efficacy, and predictability
At 3 months, 16 of 23 eyes (70%) in both groups maintained 
equal corrected distance visual acuity. Five eyes (22%) in 
the wavefront-optimized group and six eyes (26%) in the 
wavefront-guided group gained one line of corrected distance 
visual acuity. One eye in the wavefront-optimized group 
gained two lines. In each group, one eye lost one line of 
corrected distance visual acuity. In the wavefront-optimized 
group, the loss of vision was from residual astigmatism 
due to a central island. In the wavefront-guided group, the 
loss was due to irregular corneal epithelium secondary to 
superficial punctate keratopathy. No other eyes in the study 
population lost any lines of corrected distance visual acuity 
(P = 1.000, Table 3).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Preoperative group comparisons
Platform
Parameter Allegretto (n = 23) VISX (n = 23) P-value*
Age 31.4 ± 5.80
Male/female 18/5
Mean logMAr CDVA −0.06 ± 0.06 (−0.125 to 0.097) −0.07 ± 0.06 (−0.125 to 0) 0.162
CDVA (20/x) 17.8 ± 2.95 (15 to 25) 17.2 ± 2.53 (15 to 20) 0.082
spherical equivalent (D) −3.26 ± 1.82 (−8.5 to 1.5) −3.34 ± 1.75 (−8.5 to 1) 0.646
sphere (D) −3.49 ± 1.81 (−8.75 to 1.25) −3.58 ± 1.76 (−8.75 to 2) 0.589
Cyclinder (D) 0.47 ± 0.35 (0 to 2.75) 0.48 ± 0.29 (0 to 1.25) 0.665
Notes: Values represented as mean standard deviation (range); *student t test.
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAr, logarithm of the minimum angle of resolution.
Table 2 One month and 3-month visual acuity comparisons
Parameter Allegretto (n = 23) VISX (n = 23) P-value*
Postoperative month 1
UDVA (LogMAr) 0.01 ± 0.15 (−0.301 to 0.176) 0.01 ± 0.14 (−0.125 to 0.176) 0.743
UDVA (20/x) 22.6 ± 10.2 (10 to 60) 21.7 ± 7.33 (10 to 30) 0.617
CDVA (logMAr) −0.10 ± .08 (−0.301 to 0.176) −0.10 ± 0.07 (−0.301 to 0.176) 0.666
CDVA (20/x) 17.8 ± 4.96 (10 to 30) 17 ± 3.61 (10 to 30) 0.213
spherical equivalent (D) 0.15 ± 0.43 (−0.5 to 1.5) 0.15 ± 0.29 (−1.5 to 2.375) 1.000
sphere (D) −0.02 ± 0.43 (−0.375 to 1.25) −0.05 ± 0.33 (−1.5 to 1.75) 0.775
Cyclinder (D) 0.34 ± 0.31 (0 to 1) 0.40 ± 0.33 (0 to 1.25) 0.489
Postoperative month 3
UDVA (logMAr) −0.03 ± 0.07 (−0.125 to 0.097) −0.06 ± 0.09 (−0.125 to 0.176) 0.121
UDVA (20/x) 18.9 ± 3.36 (15 to 30) 17.6 ± 3.95 (15 to 25) 0.186
1 mo to 3 mo change in UDVA 0.05 ± 0.12 0.08 ± 0.12 0.276
CDVA (logMAr) −0.08 ± 0.07 (−0.125 to 0.097) −0.11 ± 0.04 (−0.125 to 0.097) 0.085
CDVA (20/x) ± ( sD 16.3 ± 22.4 (15 to 20) 16.3 ± 2.70 (15 to 25) 1.000
1 mo to 3 mo change in CDVA 0.02 ± 0.08 0.02 ± 0.07 0.714
spherical equivalent (D) 0.16 ± 0.28 (−0.375 to 0.625) 0.14 ± 0.31 (−0.375 to 0.875) 0.750
sphere (D) 0.00 ± 0.31 (−0.75 to 0.5) 0.00 ± 0.31 (−0.75 to 0.5) 0.892
Cyclinder (D) 0.33 ± 0.27 (0 to 0.75) 0.27 ± 0.25 (0 to 0.75) 0.732
Notes: Values represented as mean standard deviation (range); *student t test.
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAr, logarithm of the minimum angle of resolution.
At 1 month, 20 eyes (87%) in the wavefront-optimized 
and 21 eyes (91%) in the wavefront-guided group were 
within ± 0.50 diopters (D) of emmetropia. In addition, 16 eyes 
(70%) and 17 eyes (74%), respectively, were within ± 0.25 
D of emmetropia (P = 0.775). At 3 months, 20 eyes (87%) 
in the wavefront-optimized group and 22 eyes (96%) in the 
wavefront-guided group were within ± 0.50 D of emmetropia; 
17 (74%) and 15 (65%), respectively, were within ± 0.25 D 
(P = 1.000).
schirmer’s testing
The preoperative average Schirmer’s test value for the wave-
front-optimized group was 16.4 ± 9.43 mm and 15.9 ± 9.02 mm 
for the wavefront-guided group. At 1 month, the values were 
16.2 ± 9.75 mm and 15.8 ± 8.38 mm for the wavefront-
optimized and wavefront-guided groups,   respectively. The 
3-month postoperative values were 15.4 ± 8.89 mm for the 
wavefront-optimized and 15.7 ± 8.43 mm for the wavefront-
guided group. There were no significant changes in Schirmer’s 
testing data between both groups before or after surgery 
(P $ 0.591).
Contrast sensitivity
There were no significant changes in wavefront-optimized 
contrast sensitivity (P $ 0.137). The wavefront-guided group 
showed a significant increase in contrast sensitivity at 12 cpd 
following surgery (P = 0.013), but no significant changes at 3 
(P = 0.909), 6 (P = 0.458), or 18 cpd (P = 0.131, Figure 1).
higher-order aberrations
Three months following surgical correction, 87% of patients 
in each group completed Custom WaveScan analysis. In Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the   wavefront-optimized group, root mean square of total 
higher-order aberration (P = 0.091), coma (P = 0.115), and 
trefoil (P = 0.459) all showed an increasing trend 3 months 
postoperatively, with a statistically significant two-fold 
increase in spherical aberration (P = 0.014, Figure 2). In the 
wavefront-guided group, spherical aberration had a significant 
three-fold (P = 0.014) increase while root mean square of total 
higher-order aberration (P = 0.113), coma (P = 0.403), and 
trefoil (P = 0.603) increased, but without statistical significance 
(Figure 3). Although spherical aberration showed a statistically 
significant increase in both groups, there was no significant 
difference when comparing this change between the wavefront-
guided and wavefront-optimized platforms (P $ 0.320).
Quality of life
Mean QIRC values were obtained preoperatively and 3 months 
postoperatively (Figure 4). Postoperative mean QIRC increased 
by 31% over the preoperative mean QIRC (P , 0.001).
Complications
No intraoperative complications occurred in the study 
  population. Observed complications included superficial 
punctate keratopathy leading to loss of one line of corrected 
distance visual acuity for a patient in the wavefront-guided 
group, and a central island leading to residual astigmatism 
and loss of one line of corrected distance visual acuity for a 
patient in the wavefront-optimized group.
Table 3 Efficacy, predictability, and safety comparison of Allegretto and VISX laser platforms
Parameter
Postoperative month 1 Postoperative month 3
Allegretto (n = 23) VISX (n = 23) P-value* Allegretto (n = 23) VISX (n = 23) P-value*
Efficacy (UDVA) 0.056 0.296
20/15 or better 7 (30%) 8 (35%) 8 (35%) 14 (64%)
20/20 or better 13 (57%) 17 (74%) 20 (87%) 21 (91%)
20/30 or better 21 (91%) 22 (97%) 23 (100%) 23 (100%)
20/40 or better 22 (97%) 23 (100%) 23 (100%) 23 (100%)
20/50 or better 22 (97%) 23 (100%) 23 (100%) 23 (100%)
Predictability 1.000 1.000
(± 0.25 D of emmetropia 16 (70%) 17 (74%) 17 (74%) 15 (65%)
(± 0.50 D of emmetropia 20 (87%) 21 (91%) 20 (87%) 22 (96%)
(± 1.00 D of emmetropia 22 (97%) 23 (100%) 23 (100%) 23 (100%)
Safety (CDVA) 0.442 1.000
Loss of 2 lines 2 (9%) 0 (0%) 0 (0%) 0 (0%)
Loss of 1 line 2 (9%) 4 (18%) 1 (14%) 1 (14%)
no loss of lines 14 (61%) 15 (65%) 16 (70%) 16 (70%)
gain of 1 line 5 (22%) 4 (18%) 5 (22%) 6 (26%)
gain of 2 lines or more 0 (0%) 0 (0%) 1 (14%) 0 (0%)
Notes: Values represented as number of eyes (percentage); *student t test.
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAr, logarithm of the minimum angle of resolution.
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Note: *statistically significant (p = 0.014).
and a topography-guided platform had similar statistical 
outcomes.26 Bababeygy and Manche observed that the VISX 
CustomVue platform used in photorefractive   keratectomy 
was both safe and effective for low-to-moderate and high 
myopia, as well as compound myopic astigmatism.25 In our 
study, there were no statistically significant differences in 
outcomes of uncorrected distance visual acuity, corrected 
distance visual acuity, root mean square of total higher-
order aberration, or dry eye at 3 months postoperatively.
Our data showed a statistically significant increase in 
spherical aberration in both study platforms. However, when 
comparing the change induced by the wavefront-guided 
Discussion
There are numerous studies comparing wavefront-optimized 
and wavefront-guided platforms in LASIK, which have 
  generally shown a lack of reproducible evidence favoring one 
platform over the other.17–22 To the best of our knowledge, 
this is the first reported study comparing these platforms in 
photorefractive keratectomy. The findings of our prospective, 
randomized, fellow-eye study support previous research that 
the VISX CustomVue wavefront-guided and the WaveLight 
Allegretto wavefront-optimized platforms are both effective 
and predictable in photorefractive keratectomy.24–26   Falavarjani 
et al showed that the wavefront-optimized  Allegretto platform Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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platform with the wavefront-optimized platform, there was 
no statistically significant difference. There was a nonstatis-
tically significant increasing trend in all other higher-order 
aberration measures in both groups. Moshirfar et al also 
observed a trend similar to our results in their wavefront-
guided photorefractive keratectomy vs LASIK study, showing 
postoperative increases in root mean square total higher-order 
aberration, coma, and spherical aberration for photorefractive 
keratectomy patients at 6 months. However, they also showed 
fewer induced higher-order aberrations in the photorefractive 
keratectomy group when compared with the LASIK group.24 
Randleman et al compared wavefront-optimized photorefrac-
tive keratectomy and 3-month LASIK outcomes using the 
Allegretto platform, and, in contrast with our study, showed 
no significant induction of higher-order aberrations.16
The study showed a small statistically significant advan-
tage exclusively at 12 cpd of contrast sensitivity for the VISX 
CustomVue platform. This supports other research, because 
Awwad et al compared two wavefront-guided platforms (VISX 
CustomVue and Alcon CustomCornea) in LASIK surgery, 
and reported statistically significant improvement in contrast 
sensitivity for both platforms.27 Although we are unsure of 
the reason for this improvement in contrast sensitivity in the 
wavefront-guided group, we speculate that it may be a benefit 
of the custom ablation pattern. Further follow-up is needed to 
determine if this outcome will be sustained.
For quality of life measures, we observed significant 
increases in ratings postoperatively. Because the QIRC does 
not separate ratings based on right eye outcomes and left 
eye outcomes, we were unable to compare VISX Custom-
Vue with Allegretto WaveLight. However, Yu et al showed 
no significant difference in objective measurements on the 
QIRC questionnaire when comparing wavefront-guided 
with wavefront-optimized LASIK.28 We also administered a 
separate subjective survey; however, due to limited data, we 
were not able to derive conclusions from these data. Brief 
subjective surveys after LASIK have allowed for conclusions 
in previous literature,29 and we believe our 10-item survey 
instrument would benefit from a larger sample size.
Our study showed that one eye lost one line of corrected 
distance visual acuity in each of the study groups. The patient 
in the wavefront-optimized group was found to have residual 
astigmatism due to a central island. In the wavefront-guided 
group, the loss was determined to be due to irregular corneal 
epithelium secondary to superficial punctate keratopathy. 
Both patients have been treated with ocular lubricating agents 
and will be re-evaluated postoperatively at 6 months.
Limitations of the study include a small sample size and 
short-term follow-up. It is well known that final refractive 
and visual acuity outcomes in photorefractive keratectomy 
can take beyond 3 months to become established, although 
results are typically permanent and finalized at 6-month 
follow-up.30,31 Serrao et al recently concluded in their 6-year 
follow-up study that the higher-order aberrations after tra-
ditional photorefractive keratectomy stabilized after 1 year 
for myopia up to −9.00 D.32 Similarly, long-term analysis 
of wavefront photorefractive keratectomy can provide more 
information on stability of induced higher-order aberrations, 
which we hope to obtain in the future.
A potential limitation in comparing the VISX wavefront-
guided platform with the Allegretto wavefront-optimized 
platform is the use of the VISX CustomVue WaveScan 
aberrometer to determine higher-order aberrations for 
both platforms. The WaveScan aberrometer is specifically 
designed for the STAR S4 platform. One may argue that the 
aberrometer (WaveLight® Analyzer, Alcon Inc) made for 
use with the Allegretto platform may have shown different 
results. However, use of a single aberrometer platform to 
compare various wavefront platforms has been documented 
in the literature.18,21 A final possible limitation is the exclu-
sive use of Schirmer’s testing in our study to measure dry 
eye symptoms. Tear film stability, measured via dry eye 
symptoms and tear break-up time, may have enhanced our 
analysis on the impact of photorefractive keratectomy on 
the patients’ eyes.
In conclusion, there were no significant differences 
in visual acuity, refractive error, or dry eye between 
the wavefront-guided VISX CustomVue STAR S4 IR 
Excimer Laser with ActiveTrack iris registration and the 
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  wavefront-optimized WaveLight Allegretto Wave Eye-Q 
Laser for photorefractive keratectomy. While not statistically 
  significant, a greater percentage of patients in the wavefront-
guided group achieved 20/15 uncorrected distance visual acu-
ity. VISX CustomVue showed improved contrast sensitivity 
at 12 cpd. Both platforms induced spherical aberration after 
photorefractive keratectomy surgery at 3-month follow-up, 
and other higher-order aberration values had a tendency 
to increase as well. However, we observed no statistically 
significant difference between the changes in spherical aber-
ration when comparing the two platforms. We feel that both 
lasers are equally effective in treating refractive errors in 
photorefractive keratectomy.
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